{"entity":{"id":"nct06277154","kind":"trial","name":"MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma","aka":[],"tldr":"A phase 2 trial of Doxorubicin, Ifosfamide in vascular tumours and epithelioid sarcoma, run by HRYZ Biotech Co., now recruiting.","summary":"MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma is a phase 2 interventional study registered as NCT06277154 by HRYZ Biotech Co., with 148 participants planned, started 2024-02-21 and due to reach its primary completion in 2026-02. Interventions recorded: MASCT-I, Doxorubicin, Ifosfamide. Conditions listed: Leiomyosarcoma, Liposarcoma, Synovial Sarcoma, Angiosarcoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06277154","url":"https://clinicaltrials.gov/study/NCT06277154"}],"tags":["ctgov-ingest"],"related":[],"cancers":["vascular-tumours","epithelioid-sarcoma","rhabdomyosarcoma","uterine-sarcoma"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["doxorubicin","ifosfamide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06277154","phase":"2","setting":"A Phase II Study Evaluating the Safety and Efficacy of MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment in Patients With Advanced Soft Tissue Sarcoma","sponsor":"HRYZ Biotech Co.","participation":[{"nct":"NCT06277154","source":"https://clinicaltrials.gov/study/NCT06277154","fetchedAt":"2026-10-07T16:54:29.928Z","studySha256":"64e259c26db37981d9cd69c3e5d7a9996f63c191e4522acfc5ab165e2de71a3b","overallStatus":"RECRUITING","lastUpdatePosted":"2025-07-24","leadSponsor":"HRYZ Biotech Co.","collaboratorCount":1,"minimumAge":"18 Years","maximumAge":"70 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":148,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2024-02-21","startedType":"actual","enrolled":148,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06277154/","neighbours":{"cancer":[{"id":"epithelioid-sarcoma","kind":"cancer","name":"Epithelioid sarcoma","route":"/cancers/epithelioid-sarcoma/"},{"id":"rhabdomyosarcoma","kind":"cancer","name":"Rhabdomyosarcoma","route":"/cancers/rhabdomyosarcoma/"},{"id":"uterine-sarcoma","kind":"cancer","name":"Uterine sarcoma","route":"/cancers/uterine-sarcoma/"},{"id":"vascular-tumours","kind":"cancer","name":"Vascular tumours (angiosarcoma, epithelioid haemangioendothelioma, kaposiform haemangioendothelioma)","route":"/cancers/vascular-tumours/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"},{"id":"ifosfamide","kind":"drug","name":"Ifosfamide","route":"/drugs/ifosfamide/"}]}}